Flupirtine maleate

Research use only, not for human use.

A selective neuronal potassium channel (KCNQ/KV7 channel) activator that also has indirect NMDA receptor antagonist and GABAA receptor modulatory properties.

A selective neuronal potassium channel (KCNQ/KV7 channel) activator that also has indirect NMDA receptor antagonist and GABAA receptor modulatory properties; a centrally acting non-opioid analgesic used as an analgesic for acute and chronic pain.Pain Discontinued(In Vitro):Flupirtine (0.1, 1, and 10 mM; 24 hours) significantly reduces the growth and viability of U373 malignant glioma cells with the GI50 of 0.47 mM. Flupirtine has neuroprotective effect of on U373 MG cells.Flupirtine Maleate is active at the KCNQ and GABAA channels in the range of 10-30 μM(In Vivo):Flupirtine (5 and 10 mg/kg) induces acute neuroprotection, reduces motor coordination impairment and ameliorates recombinant tissue plasminogen activator (rtPA)-induced toxicity.

Flupirtine (0.1, 1, and 10 mM; 24 hours) significantly reduces the growth and viability of U373 malignant glioma cells with the GI50?of 0.47 mM. Flupirtine has neuroprotective effect of on U373 MG cells.Flupirtine Maleate is active at the KCNQ and GABAA?channels in the range of 10-30 μM.Cell Viability Assay Cell Line:U373 malignant glioma cell lines Concentration:0.001, 0.01, 0.1, 1, and 10 mM Incubation Time:24 hours Result:The growth of U373 MG cells was significantly reduced at high doses (1 and 10 mM) of flupirtine compared with low doses (0.001 to 0.1 mM) and control dose.

Flupirtine (5 and 10 mg/kg) induces acute neuroprotection, reduces motor coordination impairment and ameliorates?recombinant tissue?plasminogen activator?(rtPA)-induced toxicity. Animal Model:Male C57BL6 mice (22-25 g each) Dosage:1, 5, 10 mg/kg Administration:Single intraperitoneal injection during post-ischemic reperfusion Result:Both 5 and 10 mg/kg reduced infarct volumes on day 2 post-stroke, no effect was observed with 1 mg/kg.?

D-9998

Cell Cycle/DNA Damage

Potassium Channel

NMDAreceptor|PotassiumChannel

Neurological Disease

Pain

75507-68-5

420.3916

C19H21FN4O6

>98% (HPLC)

DMSO: ≥ 40 mg/mL

CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N.C(=C\C(=O)O)\C(=O)O

Carbamic acid, N-[2-amino-6-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-, ethyl ester, (2Z)-2-butenedioate (1:1)

(-20℃)

With Ice Pack

≥ 2 years